Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 240170
Corporate User License Price USD 10500
Corporate User License Price INR 720510
Site License Price USD 7000
Site License Price INR 480340
Request a Quote

Report Title

DNA-Gyrase-Subunit-B-(EC-5.99.1.3)-Pipeline-Review-H2-2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

DNA-Gyrase-Subunit-B-(EC-5.99.1.3)-Pipeline-Review-H2-2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

DNA-Gyrase-Subunit-B-(EC-5.99.1.3)-Pipeline-Review-H2-2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

DNA-Gyrase-Subunit-B-(EC-5.99.1.3)-Pipeline-Review-H2-2017



Executive Summary

DNA Gyrase Subunit B (EC 5.99.1.3)-Pipeline Review, H2 2017

Summary

DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3)-Pipeline Review, H2 2017, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

DNA Gyrase Subunit B (EC 5.99.1.3)-DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Tuberculosis, Acinetobacter Infections, Bacterial Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Klebsiella pneumoniae Infections, Mycobacterium Infections and Neisseria gonorrhoeae Infections.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)

The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects

The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

DNA Gyrase Subunit B (EC 5.99.1.3)-Overview

DNA Gyrase Subunit B (EC 5.99.1.3)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

DNA Gyrase Subunit B (EC 5.99.1.3)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

DNA Gyrase Subunit B (EC 5.99.1.3)-Companies Involved in Therapeutics Development

AstraZeneca Plc

Daiichi Sankyo Company Ltd

DNA Gyrase Subunit B (EC 5.99.1.3)-Drug Profiles

DS-2969-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GYR-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA GyrB for Tuberculosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-12008911-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXC-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXC-486-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Gyrase Subunit B (EC 5.99.1.3)-Dormant Products

DNA Gyrase Subunit B (EC 5.99.1.3)-Product Development Milestones

Featured News & Press Releases

May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017

May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AstraZeneca Plc

Daiichi Sankyo Company Ltd

DNA Gyrase Subunit B (EC 5.99.1.3) Therapeutic Products under Development, Key Players in DNA Gyrase Subunit B (EC 5.99.1.3) Therapeutics, DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline Overview, DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline, DNA Gyrase Subunit B (EC 5.99.1.3) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person